Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,
announced publication of abstracts on neratinib for the American
Association for Cancer Research (AACR) Annual Meeting 2019. The AACR
Annual Meeting will be held at the Georgia World Congress Center in
Atlanta, Georgia from March 29 to April 3. Posters will be available on
Puma’s website following presentation.

Full abstracts of the following presentations are available online at www.aacr.org:

March 31, 2019, 3:35 – 3:50 p.m. EDT – Abstract 1724 (Oral):
Natural history and clinical characteristics of ERBB2 mutant hormone
receptor-positive breast cancers: Results from the AACR Project GENIE
Registry.
Michele LeNoue-Newton et al, Vanderbilt-Ingram Cancer
Center, TN.

March 31, 2019, 3:50 – 4:05 p.m. EDT – Abstract 929 (Oral):
Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated
with neratinib reveals convergence of multiple ontarget resistance
mechanisms: Results from the SUMMIT ‘Basket’ Trial.
Helen H. Won et
al, Memorial Sloan Kettering Cancer Center, New York.

April 2, 2019, 3:20 – 3:35 p.m. EDT – Abstract 4459 (Oral):
Morphologic and genomic characterization of circulating tumor cells in
patients with ERBB2 mutant HER2 non-amplified metastatic breast
cancer treated with neratinib.
Stephanie Nicole Shishido et al,
USC, Los Angeles.

April 2, 2019, 4:35 – 4:50 p.m. EDT – Abstract 4527 (Oral):
Patient-derived organoids and xenografts identify neratinib plus HER2
antibody drug conjugate as a synergistic drug combination for HER2
mutated, non-amplified metastatic breast cancer.
Shunqiang Li et
al, Washington University School of Medicine, Saint Louis, MO.

March 31, 2019, 1:00 – 5:00 p.m. EDT – Abstract 328 (Poster):
ADAM17-induced activation of HER receptors mediate resistance to
trastuzumab in a subset of moderate HER2-expressing breast cancer cells.
Katharina
Feldinger et al, University of Birmingham, UK.

March 31, 2019, 1:00 – 5:00 p.m. EDT – Abstract 329 (Poster):
Hyperactivation of mTORC1 drives acquired resistance to the pan-HER
tyrosine kinase inhibitor neratinib in HER2-mutant cancers.
Dhivya
R. Sudhan et al, UT Southwestern Medical Center, Dallas, TX.

March 31, 2019, 1:00 – 5:00 p.m. EDT – Abstract 389 (Poster):
Role of HER3 signaling pathways in ER+ and HER2+ breast cancers.
Rosalin
Mishra et al, University of Cincinnati College of Pharmacy, Cincinnati,
OH.

March 31, 2019, 1:00 – 5:00 p.m. EDT – Abstract 395 (Poster):
Aberrant HER2 signaling is a therapeutic target in a subset of
castration-resistant prostate cancer.
Joshua W. Russo et al, Beth
Israel Deaconess Medical Center, Boston, MA.

April 1, 2019, 1:00 – 5:00 p.m. EDT – Abstract 1923 (Poster):
KRAS-mutant (mt) colorectal cancer (CRC) organoid models generated from
patient-derived xenografts (PDX) show response to combination of
trametinib (Tm), neratinib (N), and trastuzumab (Tz).
Rekha Pal et
al, NSABP Foundation, Inc., Pittsburgh, PA.

April 2, 2019, 1:00 – 5:00 p.m. EDT – Abstract 3705 (Poster):
Identification of frequent HER2 activating mutations in canine primary
pulmonary adenocarcinoma.
Gwendolen Lorch et al, Ohio State
University College of Veterinary Med., Columbus, OH.

April 3, 2019, 8:00 a.m. – 12:00 p.m. EDT – Abstract 4827
(Poster): The therapeutic superiority of neratinib in combination with
trastuzumab compared to pertuzumab plus trastuzumab in HER2-positive in
vivo breast cancer models.
Jamunarani Veeraraghavan et al,
Baylor College of Medicine, Houston, TX.

April 3, 2019, 8:00 a.m. – 12:00 p.m. EDT – Abstract 4832
(Poster): Preclinical evaluation of neratinib plus T-DM1 in orthotopic
PDX models of HER2-positive breast cancer brain metastases.
Jing Ni
et al, Dana Farber Cancer Institute, Boston, MA.

About Puma Biotechnology:

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on
the development and commercialization of innovative products to enhance
cancer care. The Company in-licenses the global development and
commercialization rights to three drug candidates — PB272 (neratinib,
oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was
approved by the U.S. Food and Drug Administration in July 2017 for the
extended adjuvant treatment of adult patients with early stage
HER2-overexpressed/amplified breast cancer, following adjuvant
trastuzumab-based therapy, and is marketed in the United States as
NERLYNX® (neratinib) tablets. NERLYNX was granted marketing
authorization by the European Commission in September 2018 for the
extended adjuvant treatment of adult patients with early stage hormone
receptor-positive HER2-overexpressed/amplified breast cancer and who are
less than one year from completion of prior adjuvant trastuzumab-based
therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.

Contacts

Puma Biotechnology, Inc.
Alan H. Auerbach or Mariann Ohanesian, +1
424-248-6500
[email protected]
[email protected]

Russo Partners
David Schull or Alex Fudukidis, +1 212-845-4200
[email protected]
[email protected]